March 22, 2023
Mitsubishi Tanabe Pharma said on March 20 that it has filed an application seeking Japanese approval for an additional OD tablet formulation for its SGLT2 inhibitor Canaglu (canagliflozin). The OD form is easier to take for patients who have difficulties...read more